Evidence map›Paper›PMID 10768951›Full record

ArticleInfection and immunity2000

Characterization and formulation of multiple epitope-specific neutralizing monoclonal antibodies for passive immunization against cryptosporidiosis.

D A Schaefer, B A Auerbach-Dixon, M W Riggs

Open access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 44 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Cryptosporidium pathogenicity and virulence.Clinical microbiology reviews · 2013
    Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

D A SchaeferDepartment of Veterinary Science and Microbiology, University of Arizona, Tucson, Arizona 85721, USA.
B A Auerbach-Dixon
M W Riggs
University of Arizona · US

Funding

PROTECTIVE ANTIGENS IN CRYPTOSPORIDIOSISU01AI030223 · NIAID · UNIVERSITY OF ARIZONA · PI STERLING, CHARLES R. · 1990 to 1996
–
MEROZOITE MONOCLONAL ANTIBODY CHARACTERIZATION AND IN VITRO C. PARVUM CULTURINGU19AI030223 · NIAID · UNIVERSITY OF ARIZONA · PI PERRYMAN, LANCE E · 1997 to 1998
–
NIAID NIH HHS AI 30223
6 · The paper itself

Abstract

The coccidian parasite Cryptosporidium parvum causes diarrhea in humans, calves, and other mammals. Neither immunization nor parasite-specific pharmaceuticals that are consistently effective against this organism are available. While polyclonal antibodies against whole C. parvum reduce infection, their efficacy and predictability are suboptimal. We hypothesized that passive immunization against cryptosporidiosis could be improved by using neutralizing monoclonal antibodies (MAbs) targeting functionally defined antigens on the infective stages. We previously reported that the apical complex and surface-exposed zoite antigens CSL, GP25-200, and P23 are critical in the infection process and are therefore rational targets. In the present study, a panel of 126 MAbs generated against affinity-purified CSL, GP25-200, and P23 was characterized to identify the most efficacious neutralizing MAb formulation targeting each antigen. To identify neutralizing MAbs, sporozoite infectivity following exposure to individual MAbs was assessed by enzyme-linked immunosorbent assay. Of 126 MAbs evaluated, 47 had neutralizing activity. These were then evaluated individually in oocyst-challenged neonatal mice, and 14 MAbs having highly significant efficacy were identified for further testing in formulations. Epitope specificity assays were performed to determine if candidate MAbs recognized the same or different epitopes. Formulations of two or three neutralizing MAbs, each recognizing distinct epitopes, were then evaluated. A formulation of MAbs 3E2 (anti-CSL [alphaCSL]), 3H2 (alphaGP25-200), and 1E10 (alphaP23) provided highly significant additive efficacy over that of either individual MAbs or combinations of two MAbs and reduced intestinal infection by 86 to 93%. These findings indicate that polyvalent neutralizing MAb formulations targeting epitopes on defined antigens may provide optimal passive immunization against cryptosporidiosis.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, ProtozoanAntigens, ProtozoanChromatography, AffinityCryptosporidiosisCryptosporidium parvumEpitopes, B-LymphocyteFemaleGlycoproteinsImmunization, PassiveMiceMice, Inbred BALB CNeutralization TestsProtozoan ProteinsProtozoan VaccinesAntibodies, MonoclonalAntibodies, ProtozoanAntigens, ProtozoanEpitopes, B-LymphocyteGlycoproteinsProtozoan ProteinsProtozoan Vaccines

Identifiers

PMID10768951
PMCPMC97466
OpenAlexW2141373390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.